Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment

Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ growth stocks to buy and hold forever. On April 9, Invivyd announced significant progress in its REVOLUTION clinical program, specifically regarding VYD2311, a monoclonal antibody candidate for COVID-19 prevention. A pre-specified analysis of the Phase 3 DECLARATION study revealed that accumulated clinical events already provide sufficient statistical power to support high-end efficacy targets.

Consequently, Invivyd has triggered a conservative upsizing of the study by ~500 subjects to ensure robust data across various scenarios. This adjustment is expected to shift the timing of top-line results slightly, moving from mid-year guidance to Q3 2026. In addition to its COVID-19 efforts, the company revealed the discovery and advancement of VMS063, a novel monoclonal antibody for the treatment and prevention of measles.

Designed to be a first-in-class precision therapy, VMS063 targets the measles Fusion protein to prevent cell entry, demonstrating high potency against circulating lineages in laboratory assays. With US measles incidence reaching decade-high levels, Invivyd Inc. (NASDAQ:IVVD) is fast-tracking VMS063 toward regulatory outreach and IND-enabling studies, with a target for IND readiness in late 2026.

Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform

Invivyd Inc. (NASDAQ:IVVD) develops next‑generation antibody drugs aimed at long‑lasting effectiveness against evolving viruses, using a proprietary platform to deliver durable therapies.

While we acknowledge the risk and potential of IVVD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IVVD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.